RxDoctor Payments DataLook up a doctor →

John Jayroe, MD

Family Medicine · Little Rock, ARNPI 1801246129

Payments from drug & device makers

$12,205in general payments, 2019–2025

Across 620 payments — averaging $19.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Amgen$1K
  • GSK$985
  • AstraZeneca$979
  • Lilly USA, LLC$882
  • Pfizer$552
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$9,378100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,205 in reported general payments places this provider in the 95th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$103,140
Medicare patients
303
Services billed
7,948

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin97$103,027
MounjaroTirzepatide81$97,726
OzempicSemaglutide66$73,447
EliquisApixaban41$30,073
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$27,937
TrulicityDulaglutide23$22,047
FarxigaDapagliflozin Propanediol15$13,353
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$6,849
SymbicortBudesonide/Formoterol Fumarate11$5,598
SynthroidLevothyroxine Sodium36$2,167
Rosuvastatin Calcium204$2,011
Dexlansoprazole DrDexlansoprazole12$1,923
Atorvastatin Calcium260$1,922
Levothyroxine Sodium184$1,798
Omeprazole124$1,725

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$882$119,773104 claims
Boehringer IngelheimJardiance$199$103,02797 claims
Novo NordiskOzempic$351$73,44766 claims
GSKTrelegy Ellipta, Anoro Ellipta$985$34,78655 claims
PfizerEliquis$552$30,07341 claims
AstraZenecaFarxiga, Symbicort$979$18,95126 claims
AbbVieSynthroid$3,919$2,16736 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →